Sonya F. Erickson is a partner in Cooley's Emerging Companies and Life Sciences practice groups and a member of the firm's Business department. She joined the firm in 2008 and is resident in the Seattle office.
Ms. Erickson's practice encompasses the representation of emerging growth companies, established technology businesses and venture capital funds.
Ms. Erickson has represented issuers and underwriters in numerous public offerings, has substantial experience in venture capital and other private financing transactions and has worked on technology-based strategic partnerships, collaborations and mergers and acquisitions. Ms. Erickson has represented over 100 private and public companies and currently serves as corporate counsel for Alder Biopharmaceuticals, Inc., ARZEDA Corporation, BEAT Biotherapeutics, Inc., Easy Metrics, Inc., EndoGastric Solutions, Inc., Seattle Genetics, Inc. (SGEN), Zettics, Inc., Zonar Systems, Inc. and Zumobi, Inc., among others.
Ms. Erickson has represented these and numerous other clients from incorporation through initial public offering, merger and beyond. She regularly advises boards of directors and audit committees with respect to the requirements of Sarbanes-Oxley and the development and implementation of best practices in corporate governance.
Prior to joining Cooley, Ms. Erickson was a shareholder at Heller Ehrman and a director and one of the founding members of the Seattle, WA office of Venture Law Group (VLG) before the merger with Heller Ehrman. Prior to that, Ms. Erickson was an associate at VLG in Menlo Park, Brobek, Phleger & Harrison in Palo Alto and Jones Day in Los Angeles. While at Heller and Venture Law Group, she represented the issuers and underwriters in several public offerings including IDEC Pharmaceuticals, SanDisk Corporation, HomeGrocer.com, Seattle Genetics, Inc., Xcyte Therapies, Inc., Pharmacyclics, Inc., Celebrate Express, Inc., Goldman Sachs and Deutsche Bank Securities. She has also been involved in many complex deals and transactions including the sale of companies to Baxter International, Elbit, Ltd., Microsoft, 3M, Research in Motion (RIM), Siemens and most recently the sale of Varolii Corporation to Nuance Communications in 2013, the sale of EKOS Corporation to BTG PLC in 2013, the sale of Full Slate, Inc. to Intuit, Inc. in 2013, the sale Blue Heron Biotechnology to OriGene Technologies in 2011, the sale of Free & Clear to Inverness Medical Innovations, Inc. in 2009, the sale of Sabrix, Inc. to Thomson Reuters in 2009, the sale of Illumigen Biosciences to Cubist Pharmaceuticals in 2008, the sale of Ikaria, Inc. to INO Therapeutics in 2007 and the sale of Qpass, Inc. to Amdocs Ltd. In 2006.
Ms. Erickson has been recognized as one of the Best Lawyers in America in the category of Venture Capital Law from 2015-2016.
Ms. Erickson earned her J.D. from the University of Washington School of Law after graduating with honors with a B.S. in Business and Economics from Pepperdine University. Ms. Erickson is admitted to practice in Washington State and is a member of the Washington State Bar Association.
- University of Washington School of Law
- Pepperdine University
BS Business and Economics, 1987, With honors
- Washington State Bar Association